Background
Paucity of dendritic cells in pancreatic cancer
Mechanisms of dendritic cell suppression
Subpopulations of dendritic cells
Maturation of dendritic cells
Aberrant antigen presentation
Crosstalk between pancreatic cancer cells and dendritic cells
Prognostic role of dendritic cells
Treatment with dendritic cell-based vaccines
Tumor associated antigens in pancreatic cancer
Tumor-associated antigen | Year | Na | Stage | Pulsation | R | SD | PD | Median survival (months) |
---|---|---|---|---|---|---|---|---|
MUC1 | ||||||||
Pecher et al. [31] | 2002 | 2 | Unresectable | cDNA | 0 | 2 | ||
Kondo et al. [32] | 2008 | 20 | Unresectable | Peptide | 1 | 5 | 14 | 9.8b |
Lepisto et al. [33] | 2008 | 12 | Resectable | Peptide | 4 | 26 | ||
Rong et al. [34] | 2012 | 7 | Unresectable | Peptide | 0 | 7 | ||
Shindo et al. [35] | 2014 | 42 | Unresectable | mRNA | 4 | 22 | 16 | 13.9 |
WT1 | ||||||||
Koido et al. [37] | 2014 | 10 | Unresectable | Peptide | 7 | 3 | ||
2015 | 7 | Unresectable | Peptide | 6 | 1 | 10.8 | ||
Mayanagi et al. [38] | 2015 | 10 | Unresectable | Peptide | 6 | 4 | 8.3 | |
Okamoto et al. [41] | 2016 | 255 | Unresectable | Peptide | 9.9 | |||
Mesothelin | ||||||||
Thomas et al. [43] | 2004 | 14 | Unresectable | Peptide | Immunological response in 3 patients | |||
KRAS | ||||||||
Gjertsen et al. [45] | 1996 | 5 | Unresectable | Peptide | 3 | 2 | 5 | |
hTERT, CEA, survivin | ||||||||
Mehrotra et al. [55] | 2017 | 12 | Unresectable | Peptide | 7.7 | |||
CEA, HER2, WT1 | ||||||||
Kimura et al. [56] | 2012 | 49 | Unresectable | Peptide | 7 | 10 | 32 | 11.8 |
CEA, MUC1 | ||||||||
Nakamura et al. [59] | 2009 | 12 | Unresectable | Peptide, lysate | 9 | |||
Tumor cell lysate | ||||||||
Bauer et al. [61] | 2011 | 12 | Unresectable | Lysate | 1 | 2 | 9 | 10.5 |